AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01644773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Starting dose level:~* Initial Treatment Plan: 130 mg/m\^2 per dose~* Modified Treatment Plan per Amendment 1.0: 165 mg/m\^2 per dose~The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.~The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.~Cycle 1 (28 days): once a day for 28 days~Cycles 2-26 (28 days each): once a day
Study NCT01644773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Starting dose level: 50 mg/m\^2 per dose~The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.~The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.~Cycle 1 (28 days): starting on day 3, once a day for 28 days~Cycles 2-26 (28 days each): once a day
Study NCT02771418 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Propofol
Description: Intravenous induction and maintenance of general anesthesia with propofol is a routine practice for this intervention
Study NCT02771418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Volatile induction and maintenance of general anesthesia with sevoflurane is a generally acceptable clinical approach for this intervention
Study NCT02780063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lenstar Biometer
Description: uses optical principles (laser interferometry) to measure axial length, measuring distance from the corneal apex to the retinal RPE. In addition to axial length, it also measures corneal thickness, anterior chamber depth, lens thickness, radii of curvature of flat and steep meridian, axis of flat meridian, white to white distance, and pupil diameter.
Study NCT03594734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Lifestyle Balance™
Description: The Group Lifestyle Balance™ (GLB) program is a self-management intervention that has been shown to result in weight-loss and reduce the risk for Type 2 diabetes through increased physical activity and healthy eating behaviors in the general population. The GLB program curriculum used in this RCT will be adapted for individuals with TBI.
Study NCT03594734 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Group
Description: The attention control group will receive the same contact or attention as the intervention group. The attention control group will meet at the same frequency as the intervention group. Education for the sessions will be composed of content from the TBI Model Systems Knowledge Translation Center's factsheets. General topics will include discussion on (1) healthy brain and effects of TBI on cognitive, emotional, and behavioral functioning, (2) expectations for recovery, (3) preventative and management strategies for common TBI sequela (e.g. inability and impulsivity), (4) stress management, (5), signs and symptoms of depression, and (6) strategies for effective communication.
Study NCT00569270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Procedure/Surgery - tiotropium 18ug capsule daily for 1 month vs placebo to study the effect of trough and peak effect on bronchodilation and effect of metronome paced hyperventilation induced dynamic hyperinflation
Study NCT02771418 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Elective carotid endarterectomy
Study NCT02771418 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elective carotid endarterectomy
Study NCT00569270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Procedure/Surgery - tiotropium 18ug capsule daily for 1 month vs placebo to study the effect of trough and peak effect on bronchodilation and effect of metronome paced hyperventilation induced dynamic hyperinflation
Study NCT04189575 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS Intervention
Description: Delivery of text messages will use the Rip Road Mobile platform.
Study NCT02857582 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultured human intestinal microbiota
Description: Secondary treatment for C diff in replacement for regular vancomycin.
Study NCT02857582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Active comparator to treatment with ACHIM
Study NCT03561558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen D
Description: Ibuprofen D, oral suspension, 200 mg / 5ml, manufactured by LLC Pharmtechnology, Belarus
Study NCT03561558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nurofen® for Children
Description: Nurofen® for Children, Oral Suspension, 100 mg / 5 ml, marketed by Reckitt Benckiser Healthcare International Ltd, UK
Study NCT03098186 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention SMS
Description: The active treatment will consist of SMS that are aimed to modified behavioral factors associated with poor adherence to cardiovascular medications used in secondary prevention. The SMS will be delivered daily during the first month, increasing one day of interval for each week during the second month , and weekly thereafter until end of month 12th. In addition, they will receive SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
Study NCT03098186 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control SMS
Description: Participants will only receive the SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
Study NCT04542915 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention.
Study NCT04461340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: oral dose of 6 mg on day1 followed by 2 mg daily for 9 days
Study NCT01601938 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenium replacement
Description: Selenium 500 mcg (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.
Study NCT01601938 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.
Study NCT02312479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nyxoah SAT system
Description: The Nyxoah SAT system is comprised of an implantable nerve stimulator implanted over one of the tongue muscles via a minimally invasive procedure. Stimulation of the Hypoglossal nerves causes the tongue muscles to contract, thus maintaining an open airway during sleep.
Study NCT01936311 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management goal elicitation
Description: The intervention will be a form, given prior to a primary care visit, that allows patients to express a self-management goal (health goal) they would like to work on, and a preferred treatment modality.
Study NCT02857582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Primary treatment for C diff in all treatment arms
Study NCT02857582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Primary treatment for C diff in all treatment arms
Study NCT03287687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) gas insufflation
Description: CO2 gas use for insufflation during endoscopy instead of air insufflation
Study NCT03287687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Air insufflation
Description: Air insufflation is the standard of practice (used in the control arm)
Study NCT04293731 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Symbiter-Smectite
Description: Symbiter-Smectite contains biomass of alive probiotic microorganism symbiosis, colony forming units - CFU/g: Lactobacillus - 1.0х109, Bifidobacterium - 1.0х109, Lactococcus - 1.0х108, Propionibacterium - 1.0х108 and Acetobacter - 1.0х105; and smectite gel (250 mg)
Study NCT04293731 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02728622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: endocrine treatment
Study NCT02728622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Paclitaxel or pegylated liposomal doxorubicin
Study NCT02662634 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-003-LNG
Description: autologous dendritic cell immunotherapy
Study NCT02662634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent.
Study NCT02662634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Paclitaxel destroys cancer cells by preventing the normal breakdown of microtubules during cell division.
Study NCT02662634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alimta
Description: By inhibiting the formation of precursor purine and pyrimidine nucleotides, pemetrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cell
Study NCT01264913 — intervention group
Intervention type: BEHAVIORAL
Intervention: sleep extension & circadian alignment
Description: Both groups of workers will undergo a 1-week period of fixed bedtimes, light-dark cycles and mealtimes in the laboratory to pay the sleep debt and align the circadian system
Study NCT02662634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Binds to and causes crosslinking of DNA, which ultimately triggers apoptosis
Study NCT02662634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: Mechanism of action involves interference with the normal breakdown of microtubules during cell division.
Study NCT02662634 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Causes DNA strand breaks.
Study NCT01736462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mapracorat
Description: One drop of mapracorat ophthalmic suspension, 3% four times daily, at approximately four hour intervals, for 14 days in both eyes.
Study NCT02091908 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novartis Investigational H5N1 vaccine
Description: 2 doses of 0.5 ml, 3 weeks apart
Study NCT02091908 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Novartis Seasonal Influenza Vaccine
Description: 2 doses of 0.5 ml, 3 weeks apart
Study NCT01044251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Frovatriptan
Description: 2.5 mg po bid for 10 days
Study NCT01044251 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tab po bid for 10 days
Study NCT00734370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy for agoraphobic participants
Description: This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of~* Psycho-education, breathing training and cognitive restructuring~* Virtual reality Exposure to agoraphobic situations and interoceptive exposure~* Relapse prevention
Study NCT00734370 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard exposure in vivo for agoraphobic participants
Description: This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of~* Psycho-education, breathing training and cognitive restructuring~* Standard exposure in vivo to agoraphobic situations and interoceptive exposure~* Relapse prevention (according to the protocol of Craske \& Barlow)
Study NCT01462643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS41004
Description: once daily, topical ointment, 100 microgram per day
Study NCT01462643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004
Description: once daily, topical ointment, 100 microgram per day
Study NCT01462643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LAS41004
Description: once daily, topical ointment, 100 microgram per day
Study NCT04668573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trunk exercise
Description: Trunk exercise includes trunk muscles stretching, trunk muscles strengthening, and task-related trunk control training for 30 minutes per session, twice a week for 12 weeks.
Study NCT04079010 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BFR
Description: Blood flow restriction (BFR) training is a non-invasive technique that uses wraps, bands, or inflated blood pressure cuffs to change blood flow within targeted muscles. Occlusion pressure of the femoral artery will be determine before each training session using the Delfi Personalize Tourniquet System for Blood Flow Restriction (2.0) which has embedded ultrasound technology to continually measure the blood flow and with auto-adjust the pressure. The target percent of occlusion is 50% of total blood flow while completed a prescribed resistance training regimen 4 times per week.
Study NCT04079010 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arginine
Description: The BFR+Arg group will consume Arginine supplement daily throughout the course of the study. Supplements were manufactured by Kyowa, a US-based cGMP-compliant contract manufacturing facility independently audited and pre-qualified by the quality compliance firm, Obvium\*Q, LLC (Dallas, TX). Manufacturing batch records for production of each of the supplements were maintained by the manufacturer and finished supplements were independently assayed for identity, purity, potency, and composition using appropriate USP, AOAC, or BAM methods at the independent, analytical laboratory, Dyad Labs (Salt Lake City, UT), prior to approval for release and consumption of the supplements by participants.~Each serving of the supplements were formulated to contain 3,000 mg L-Arginine (ARG; Kyowa). Each supplement also contained the inert and non-insulinotropic excipient ingredients, microcystalline cellulose and silicon dioxide.
Study NCT04079010 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Pill
Description: The CON and BFR groups will consume placebo pill daily throughout the course of the study. Supplements were manufactured by Kyowa, a US-based cGMP-compliant contract manufacturing facility independently audited and pre-qualified by the quality compliance firm, Obvium\*Q, LLC (Dallas, TX). Manufacturing batch records for production of each of the supplements were maintained by the manufacturer and finished supplements were independently assayed for identity, purity, potency, and composition using appropriate USP, AOAC, or BAM methods at the independent, analytical laboratory, Dyad Labs (Salt Lake City, UT), prior to approval for release and consumption of the supplements by participants.~Each serving of the supplements were formulated to contain 3,000 mg Maltodextrin placebo (PLA; MALTRIN-M100; Grain Processing Corporation; Muscantine, IA). Each supplement also contained the inert and non-insulinotropic excipient ingredients, microcystalline cellulose and silicon dioxide.
Study NCT04079010 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pill
Description: The CON and BFR groups will consume placebo pill daily throughout the course of the study. Supplements were manufactured by Kyowa, a US-based cGMP-compliant contract manufacturing facility independently audited and pre-qualified by the quality compliance firm, Obvium\*Q, LLC (Dallas, TX). Manufacturing batch records for production of each of the supplements were maintained by the manufacturer and finished supplements were independently assayed for identity, purity, potency, and composition using appropriate USP, AOAC, or BAM methods at the independent, analytical laboratory, Dyad Labs (Salt Lake City, UT), prior to approval for release and consumption of the supplements by participants.~Each serving of the supplements were formulated to contain 3,000 mg Maltodextrin placebo (PLA; MALTRIN-M100; Grain Processing Corporation; Muscantine, IA). Each supplement also contained the inert and non-insulinotropic excipient ingredients, microcystalline cellulose and silicon dioxide.
Study NCT03883399 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Survey among colorectal surgeons
Study NCT03308955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
Study NCT03308955 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Tramadol
Description: 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
Study NCT03308955 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided Quadratus Lumborum block
Description: Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg % 0.25 bupivakain+400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
Study NCT03308955 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Ultrasound guided placebo Quadratus Lumborum block
Description: Ultrasound guided placebo Quadratus Lumborum block type II with 0.3 ml/kg saline % 0,9+400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
Study NCT00484094 — intervention group
Intervention type: DRUG
Intervention: sirolimus
Description: Dosage and treatment duration will be decided by physician's discretion considering patient's clinical situations
Study NCT01881373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHL program
Description: Multiple component environmentally focused program designed with community engagement.
Study NCT01881373 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Delayed Optimized CHL program
Description: CHL programs with fewer component and shorter duration.
Study NCT02735408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape (KT)
Study NCT04296110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: They will also be taught how to use the biofeedback app and Inner Balance device. Additionally, they will also be educated on the principles of biofeedback and its benefits and taught how to maximize HRV by using self-regulation breathing techniques.They will be given an Inner Balance device, which is an ear sensor that connects to an apple device that measures heart rate variability (HRV) and gives them access to an app that is designed to help them improve their HRV. They will be asked to practice breathing at their resonance frequency using the Inner Balance device daily for 5-15 mins for the duration of the 12-week intervention. Patients and the research coordinator will have access to all of their sessions and results. The research coordinator will monitor compliance via the Heartcloud associated with their device and encourage adherence throughout the intervention.
Study NCT04296110 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Relaxation Therapy
Description: We will determine what genre of music is most relaxing to them and ask them to listen to this type of music using the spotify app for 5-15 mins a day for 12 weeks. If they do not have access to a device that they can listen to spotify on, an ipod will be provided. They will be asked to complete a 2-question survey via Redcap daily that asks them if they have listened to the designated music that day and for how long.
Study NCT01628172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biosense Webster Celcius Thermacool catheter
Description: catheter-based sympathetic renal denervation
Study NCT04597775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: hydroxychloroquine
Study NCT04597775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxychloroquine
Description: hydroxychloroquine
Study NCT01892189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063
Description: TAK-063 tablets
Study NCT03526575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zolpidem
Study NCT03426696 — intervention group
Intervention type: BEHAVIORAL
Intervention: psychological condition
Description: Graves ́ ophthalmopathy quality of life questionnaire, Symptom checklist 90(SLC-90), Hamilton anxiety scale(HAMA), Somatic self-rating scale(SSS), MATRICS Consensus Cognitive Battery (MCCB), Hamilton depression scale(HAMD)
Study NCT03875690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of methylprednisolone
Description: Patients will receive 20mg/kg IV of methylprednisolone at the time of anaesthetic induction. Methylprednisolone will be infused in a ready-to-use 50 mL bag of sodium chloride 0.9% during 30 minutes at anaesthesic induction.